K6PC-5, a ceramide analogue, is a sphingosine kinase 1 (SPHK1) activator that causes a transient and rapid increase in intracellular calcium levels. K6PC-5 is used to study skin diseases, neurodegenerative diseases and viral infections involving abnormal keratinocytes.

Physicochemical Properties

Molecular Formula	C19H37NO4
Molecular Weight	343.508
Exact Mass	343.272
CAS #	756875-51-1
PubChem CID	11660192
Appearance	White to off-white solid powder
LogP	3.812
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	16
Heavy Atom Count	24
Complexity	329
Defined Atom Stereocenter Count	0
InChi Key	CGYVFCHCRBGGJG-UHFFFAOYSA-N
InChi Code	InChI=1S/C19H37NO4/c1-3-5-7-9-11-13-18(23)17(12-10-8-6-4-2)19(24)20-16(14-21)15-22/h16-17,21-22H,3-15H2,1-2H3,(H,20,24)
Chemical Name	N-(1,3-dihydroxypropan-2-yl)-2-hexyl-3-oxodecanamide
Synonyms	K6PC5 K6PC 5 K6PC-5
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	K6PC-5 (1-10 μM; 24 hours) dose-dependently raises the levels of loricin and involucrin in normal human emergency response (NHEK) cells. K6PC-5 uses intracellular Ca2+ nutritional signaling to encourage the creation of new cells. Furthermore, c-Jun N-terminated division phosphorylation and p42/44 extracellular signal regulation are stimulated by K6PC-5 [1]. K6PC-5 (1–10 μM; 24 h) stimulates human fibroblasts and causes oscillations in the intracellular Ca2+ concentration ([Ca2+]i) in these cells [2]. In EA.hy926 cells infected with EBOV, K6PC-5 (10, 25, and 50 μM; 48 hours) dramatically decreased EBOV-induced infection. In cell supernatants, K6PC-5 dramatically lowers viral titers and, in a concentrated way, greatly lowers VP40 levels [3].]
ln Vivo	In an inherently aged hairless mouse (56 weeks old), 1% K6PC-5 was topically administered for 2 weeks. This K6PC-5 therapy greatly enhanced the number of cutaneous fibroblasts and collagen synthesis. Therefore, dermal thickness is also greatly raised in
Cell Assay	Western Blot Analysis[1] Cell Types: Normal human epidermal keratinocytes (NHEK) Tested Concentrations: 1 μM, 5 μM, 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: Involucrin and loricin levels increased in a dose-dependent manner. Cell proliferation experiment [2] Cell Types: human fibroblasts Tested Concentrations: 1 μM, 5 μM, 10 μM Incubation Duration: 24 h Experimental Results: Dramatically promoted human fibroblast proliferation and procollagen production.
Animal Protocol	Animal/Disease Models: Intrinsically aged hairless mice (56 weeks old) [2] Doses: 1% (Vehicle (PEG:EtOH = 7:3)) Route of Administration: Topical application; [2 ]. twice (two times) daily for 2 weeks Experimental Results: Enhanced fibroblast proliferation, collagen production, and ultimately increased dermal thickness.
References	[1]. Novel synthetic ceramide derivatives increase intracellular calcium levels and promote epidermal keratinocyte differentiation. J Lipid Res. 2007 Sep;48(9):1936-43. [2]. K6PC-5, a sphingosine kinase activator, induces anti-aging effects in intrinsically aged skin through intracellular Ca2+ signaling. J Dermatol Sci. 2008 Aug;51(2):89-102. [3]. The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection. iScience. 2021 Mar 5;24(4):102266.

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL (~291.12 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.9111 mL	14.5556 mL	29.1112 mL
	5 mM	0.5822 mL	2.9111 mL	5.8222 mL
	10 mM	0.2911 mL	1.4556 mL	2.9111 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.